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Abstract
Introduction: An increasing incidence rate of respiratory isolates of non-tuberculous mycobacteria (NTM) has been noted recently 
in most European countries as well as in the US. Despite many publications, there is no consensus concerning the importance of 
different factors in promoting NTM lung disease (NTMLD). 
The aim of the present retrospective study was to analyse patients with positive NTM respiratory isolates in search of factors 
predisposing to NTMLD. 
Material and methods: 73 patients, 23 males, 50 females, median age 62.2 years, in whom NTM have been cultured from 
respiratory specimen (sputum and/or bronchial washings), in the period 2010–2015, entered the study. 
Results: NTMLD (according to ATS/IDSA) has been recognised in 36 patients, airways colonisation by NTM — in 37 patients. NTMLD 
was diagnosed more often in the patients infected with M. kansasii, M. abscessus and M. avium/M. intracellulare comparing to those 
infected with M. xenopi, M. gordonae and M. fortuitum (p < 0.0001). The proportion of females to males was significantly higher in 
the NTMLD group comparing to the colonisation group (p < 0.007). Previous tuberculosis or mycobacteriosis were noted significantly 
more frequently in the group of patients with NTMLD comparing to the colonisation group (28% vs 8%, p = 0.038). Univariate regres-
sion analysis revealed M. kansasii, female gender, and previous tuberculosis or mycobacteriosis as significant predictors of NTMLD. 
Conclusions: The risk factors of NTMLD recognition in the presented group of patients were the following: female gender, 
M. kansasii isolation, as well as past tuberculosis or mycobacteriosis. 
Key words: non-tuberculous mycobacteria, COPD, bronchiectasis, interstitial lung disease, corticosteroids
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Introduction
Non-tuberculous mycobacteria (NTM) are 
environmental organisms, present in natural 
and artificial water sources as well as in dust 
and in soil [1, 2]. They may colonise human 
bronchial, gastrointestinal and urinary tracts, 
causing no symptoms of the disease, never-
theless, in some individuals NTM may be 
pathogenic [3]. 
The increasing incidence rate of respiratory 
isolates of NTM as well as NTM caused lung di-
sease (NTMLD) has been noted recently in most 
European countries as well as in the US [4–8]. 
This concerns especially the increase of M. avium, 
M. fortuitum and M. abscessus [4, 5, 8, 9]. The 
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growing incidence of NTM caused lung disease is 
probably brought about by an increasing number 
of patients with risk factors, such as chronic lung 
diseases, immunosuppressive treatment as well 
as aging of the population [4, 8, 10–12]. 
NTM isolation from a respiratory specimen 
is not an unambiguous sign of NTMLD. The 
criteria of NTMLD are defined in the ATS/IDSA 
recommendations from 2007 [13] and the latest 
BTS recommendations [14]. The proportion of 
patients with positive respiratory isolates of 
NTM, in whom NTMLD is diagnosed depends 
on the pathogenic characteristics of NTM and 
clinical characteristics of the population [15]. 
Despite many publications, there is no consen-
sus in the literature concerning the importance 
of different factors in promoting NTMLD deve-
lopment. 
Thus, the aim of the present retrospective stu-
dy was to analyse the clinical and microbiological 
data in search of factors predisposing to NTMLD 
in the population of patients with positive NTM 
respiratory isolates. 
Material and methods
Population
73 patients, 23 males, 50 females, median age 
62.2 years (20–85 years), in whom non-tuberculo-
us mycobacteria (NTM) have been cultured from 
respiratory specimens (sputum and/or bronchial 
washings), in the period from 2010 to 2015, en-
tered the study. The study approval was obtained 
from Ethics Committee (no 9/2015).
Diagnostic criteria
The criteria of the recognition of non-tuber-
culous mycobacterial lung disease (NTMLD) have 
been applied according to the ATS/IDSA recom-
mendations (Table 1) [13]. The factors potentially 
influencing development of NTMLD, such as: age, 
gender, body mass index (BMI), smoking habits, 
comorbidities and their treatment, were analysed. 
NTM cultures and identification
The respiratory specimens (sputum and/or 
bronchial washings) were decontaminated with 
the sodium hydroxide and N-acetyl-L-cysteine 
(NaOH/NALC) method. The strains were cultured 
on solid media: egg-based Lowenstein-Jensen 
medium, Stonebrink medium and in automated 
system MGIT (Becton Dickinson). 
Identification of culture was performed using 
the molecular test GenoType CM (Hain Lifescience), 
version 1.0 and 2.0. The procedure for identifying 
strains consists of three steps: isolation of DNA, 
amplification using primers labeled with biotin and 
a reverse hybridisation. The GenoType CM test using 
the DNA-STRIP method allows the identification of 
Mycobacterium tuberculosis complex strains and 14 
clinically relevant NTM within a single procedure. 
Statistical methods
Data were analysed in R environment [16]. 
The differences between the groups concerning 
the distribution of categorical variables were 
assessed with chi-square test. Wilcoxon rank 
sum test with continuity correction was used for 
the comparison of continuous variables in two 
different groups. Univariate logistic regression 
concerning prediction of NTMLD was performed 
and odds ratios with its 95% confidence interval 
were calculated, p-value < 0.05 was considered 
as statistically significant. 
Results
NTMLD has been recognised in 36 patients, 
airways colonisation by NTM — in 37 patients. 
Demographic data and smoking habits in the 
group of NTMLD versus the group with NTM 
colonisation are presented in Table 2.
The proportion of females to males was signi-
ficantly higher in the NTMLD group comparing to 
the colonisation group. A tendency towards lower 
age and BMI was noted in the NTMLD group 
comparing to the colonisation group. 
Table 1. Principles of recognition of NTMLD according to ATS/IDSA [13]
Clinical 1. Pulmonary symptoms, nodular or cavitary opacities on chest radiograph, or a high-resolution CT scan that shows mul-
tifocal bronchiectasis with multiple small nodules 
and
2. Appropriate exclusion of other diagnoses
Microbiologic 1. Positive culture results from at least two separate expectorated sputum samples 
or 
2. Positive culture results from at least one bronchial wash or lavage
or
3. Transbronchial or other lung biopsy with mycobacterial histopathological features (granulomatous inflammation or 
acid fast bacilli) and positive culture for NTM of: lung specimen, bronchial wash or sputum (at least one)
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Table 2. Demographic data and smoking habits according to final diagnosis in 73 patients with positive respiratory isolates 
for non-tuberculous mycobacteria (NTM)
Diagnosis No of pts Age (years. median, 
range)
Males/females Smokers
No (%) 
BMI (kg/m2),
mean, SD
NTMLD 36 58.5
(20–85)
6/30* 16 (44) 22.7
(± 4.74)
NTM colonisation 37 66.2
(20–78)
17/20* 17 (46) 24.4
(± 5.04)
Total 73 62.2
(20–85)
23/50 33 (45) 23.7
(± 4.9)
*p = 0.007; NTMLD: non-tuberculous mycobacterial lung disease; BMI: body mass index; SD: standard deviation
Table 3.  Distribution of NTM species according to final diagnosis in 66 patients with positive respiratory isolates for  
single non-tuberculous mycobacteria (NTM)
Diagnosis No of 
pts
 NTM species
M.
kansasii
M. avium M. intracel. M.
abscessus
M.
gordonae
M.
fortuitum
M.
xenopi
NTMLD 33 13 10 4 2  1 0 3
NTM
colonisation
33  3  6 2 0 13 4 5
Total 66 16 16 6 2 14 4 8
NTMLD: non-tuberculous mycobacterial lung disease
The NTM species identification revealed: 
M. kansasii — in 16 patients (22%), M. avium — in 
16 (22%), M. gordonae — in 14 (19%), M. xeno-
pi — in 8 (11%), M. intracellulare — in 6 (8%), 
M. fortuitum — in 4 (6%), M. abscessus — in 
2(3%), more than one type of mycobacteria — in 
7 patients (10%). The distribution of NTM species 
in the NTMLD group comparing to the colonisa-
tion group, was performed in 66 patients with 
a single respiratory NTM isolate (Table 3).
NTMLD has been diagnosed in both indi-
viduals infected with M.abscessus, in 81% of 
patients infected — with M.kansasii, 64% of 
subjects infected with M. avium/M. intracellula-
re, 38% of those with M. xenopi, 7% of infected 
with M. gordonae and none — with M. for-
tuitum. The proportion of NTMLD among patients 
with more pathogenic NTM types (M. abscessus, 
M. kansasii and M. avium/M. intracellulare) and 
those less pathogenic (M. xenopi, M. gordone, 
M. fortuitum) — were 29/40 (73%) and 4/26 (15%), 
respectively, p < 0.0001. 
In majority of patients — 70/73 (96%), coexi-
sting diseases that could predispose to NTMLD 
were noted: in 25/73 (34%) — one, in 26/73(36%) 
— two, and in 19/73(26%) — more than two dise-
ases. Analysis of coexisting disorders is presented 
in table 4. Most frequent comorbidities were: 
bronchiectasis — in 24 patients — 33%, chronic 
obstructive pulmonary disease (COPD) — in 18 
individuals (25%) and interstitial lung diseases 
(ILD) — in 18 subjects (25%): lung fibrosis due 
to collagen tissue disease (4 cases), cryptogenic 
organising pneumonia (3), sarcoidosis (3), hy-
persensitivity pneumonitis (2), Langerhans cell 
histiocytosis (1), NSIP (1), lung fibrosis not clas-
sified (4). Oral corticosteroids (CS) were used by 
17 (23%) patients, in 10 — as the only therapy, in 
7 — combined with immunosuppressive thera-
py. The median prednisone dose was 10 mg/day 
(range 5–40 mg). Immunosuppressive drugs were 
used by 9 (12%) patients: azathioprine 100–150 
mg/day — by 4, methotrexate 10 mg/week — 1, 
rituximab — 1, hydroxychloroquine — 1, and 
systemic chemotherapy due to lung cancer — by 
2 individuals. 
The influence of various pre-existing diseases 
on NTMLD development has been investigated 
(Table 4). Previous tuberculosis or mycobacte-
riosis were noted significantly more frequently 
in the group of patients with NTMLD comparing 
to the colonisation group (28% and 8%, respecti-
vely, p = 0.038). COPD was diagnosed more often 
in the colonisation group comparing to NTMLD 
(30% and 19% respectively), nevertheless, the 
differences were not significant. 
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Table 4.  Coexisting diseases and their treatment according to final diagnosis in 73 patients with positive respiratory iso-
lates for non-tuberculous mycobacteria (NTM)
Coexisting 
disease
NTMLD 
36 pts
no (%)
Colonisation 
37 pts
no (%)
Total
73 pts
no (%)
p
Bronchiectasis 12 (33) 12 (33) 24 (33) 0.94
COPD 7 (19) 11 (30) 18 (25) 0.25
Astma/ABPA 2 (6) 5 (14) 7 (10) 0.24
ILD 10 (28) 8 (22) 18 (25) 0.63
CTD 5 (14) 5 (14) 10 (14) 1.0
CF 3 (8) 1 (3) 4 (6) 0.63
NPL 9 (25) 7 (19) 16 (22) 0.62
Diabetes 4 (11) 9 (24) 13 (18) 0.19
Hypothyreosis 8 (22) 6 (16) 14 (19) 0.59
Previous tbc/myco 10 (28) 3 (8) 13 (18) 0.038
None 2 (6) 1 (3) 3 (4) 0.52
Systemic glucocorticoids 10 (28) 7 (19) 17 (23) 0.53
Immunosuppressive
drugs
4 (11) 5 (14) 9 (12) 0.97
NTMLD: non-tuberculous mycobacterial lung disease; COPD: chronic obstructive pulmonary diseas; ABPA: allergic bronchopulmonary aspergillosis; ILD: interstitial lung 
diseases (details in the text); CTD: collagen tissue diseases-mixed collagen tissue disease (1), rheumatic polymyalgia (1), autoimmunological cholangitis (2), primary 
biliary cirrhosis (1), rheumatoid arthritis (2), CTD- not classified (2), Sjogren’s syndrome (1); CF: cystic fibrosis; NPL: previous or actual neoplastic disease — lung 
cancer (6), lymphoma (2), colon cancer (2), breast cancer (1), gastric cancer (1), urinary bladder cancer (1), thyroid gland cancer (1), uterus cancer (1), basocellular 
skin cancer (1)
Table 5. Factors significantly influencing NTMLD reco-
gnition, univariate regression analysis
 Univariate regression analysis
Factor OR 95%CI p
M. kansasii 4.87 1.42–16.72 0.012
M. gordonae 0.044 0.005–0.36 0.003
Female gender 3.69 1.23–11.05 0.02
Age 0.96 0.927–0.999 0.041
BMI 0.894 0.805–0.992 0.035
Previous TBC, NTMLD 4.074 1.018–16.306 0.047
OR: odds ratio; CI: confidence interval; BMI: body mass index; TBC: tuberculo-
sis; NTMLD: non-tuberculous mycobacterial lung disease
The proportions of ILD and collagen tissue 
disease (CTD) in the groups of NTMLD and colo-
nisation were equal. In the patients with NTMLD 
comparing to colonisation, the percentages of 
individuals treated with corticosteroids alone or 
in combination with immunosuppressive therapy 
were: 28% and 19 % respectively, with the diffe-
rence being nonsignificant. 
Univariate analysis of factors possibly in-
fluencing NTMLD development is presented in 
table 5. The elements significantly increasing 
probability of NTMLD were: M. kansasii isola-
te, female gender, and previous tuberculosis or 
mycobacteriosis. The risk of NTMLD was lower 
in those diagnosed with M. gordonae, older ones 
and those with higher BMI. 
Discussion
The analysis of factors predisposing to 
NTMLD development in our material revealed 
that women were more susceptible than men. 
Female gender was confirmed as a risk factor of 
NTMLD in univariate analysis. 
The published data concerning this subject 
are discrepant. Adzic et al. [6] documented that 
66% of NTMLD cases registered between 2009 
and 2016 in the University Hospital for Pulmono-
logy in Belgrade involved men. US epidemiologi-
cal studies concerning NTM respiratory isolates 
registered by Integrated Health Care Delivery Sys-
tems (2004–2006) found females’ predominance 
[11, 17, 18]. It seems that males predominate in 
the group of patients with NTMLD and underlying 
COPD [6, 19], whereas females — in the cate-
gory of bronchiectatic form of NTMLD [15, 17]. 
Especially, the nodular bronchiectatic type of 
disease observed in non-smoking, thin and tall, 
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postmenopausal women, with pectus excavatum, 
and mitral valve prolapse (MVP), called Lady Win-
dermere syndrome, may be responsible for female 
predominance in some published series [3, 20]. 
In our study, 3 non-smoking, postmenopausal 
women, with BMI 19.7–23.6 were identified, 
nevertheless, without MVP or pectus excavatum. 
The microbiological analysis of our group 
of patients revealed that the most pathogenic 
among NTM species was M. kansasii (NTMLD 
developed in 81% of infected patients), and it 
was found to be an independent risk factor of 
NTMLD diagnosis. Another study coming from 
Poland confirmed high virulence of M. kansasii 
reporting clinically relevant lung disease in 82% 
of infected patients [21]. 
M. abscessus was identified by us in two 
patients only, nevertheless, both presented with 
NTMLD. Recent US report demonstrated the in-
crease of NTM species belonging to M. abscessus 
group between 1994 and 2014 by 322% [4]. The 
current proportion of NTMLD caused by M. ab-
scessus is 20% in Europe and 15% in Japan [22].
NTM belonging to M. avium/M. intracellulare 
complex (MAC) were less pathogenic in our mate-
rial, nevertheless, in 64% of the patients infected 
with these strains NTMLD has been recognised. 
Although MAC is less pathogenic than M. kansa-
sii, it is the cause of most cases of lung disease in 
the US, Europe and Japan, due to a high rate of 
identification, especially in the aging population 
[17, 22, 23]. 
The present study revealed high frequency 
of coexisting diseases that could predispose to 
NTM colonisation. 96% of patients had at least 
one illness diagnosed. 
Among chronic lung diseases, the most frequ-
ent were COPD and bronchiectasis diagnosed in 
25% and 33% of patients, respectively. 
The relation between COPD and NTMLD has 
been the subject of many studies published recen-
tly. Hoefsloot et al. [24] found a 22% prevalence 
of NTM isolation in 73 consecutive patients with 
COPD exacerbation, the subjects with positive 
culture were significantly older than the others. 
Char et al. [25] confirmed the presence of necro-
tising granulomas in 10% of COPD patients, in 
whom lung volume reduction surgery has been 
performed. 
The increased risk of NTMLD in COPD sub-
jects may be partly associated with inhaled 
steroids use and dosage [26, 27]. Diel et al. [28] 
found an increased mortality rate among COPD 
individuals infected with NTM, comparing to 
those not infected.
Up to 30% of COPD patients are diagnosed 
with COPD-bronchiectasis overlap syndrome [29]. 
Gatheral et al. [30] found radiographic presence 
of bronchiectasis in 69% of COPD patients ad-
mitted with first exacerbation. The presence of 
bronchiectasis in COPD independently determi-
ned sputum isolation of P. aeruginosa and NTM 
[30] and correlated with increased frequency of 
exacerbations and mortality [31]. 
Recently published population survey from 
Israel revealed the presence of positive respirato-
ry isolates for NTM in 105/6274 (1.7%) patients 
with bronchiectasis [32]. The authors indicated 
female gender, age below 65 years, and antibiotic 
or prednisolone therapy as risk factors for NTM 
colonisation [32]. A multicentre, epidemiologi-
cal study, conducted in the US, concerned the 
possible risk factors of NTMLD in two national 
samples of bronchiectasis patients [33]. Inha-
led corticosteroids use have been reported by 
30–40% of patients, in 60% of them for the time 
longer than 1 year [33]. These data indicate that 
further research is needed to clarify the safety 
of inhaled corticosteroids in the patients with 
bronchiectasis. 
ILD have been noted in 25% of our group with 
positive NTM isolates. Various types of ILD have 
been recognised. NTM have been cultured in tho-
se with prolonged course of disease, lung fibrosis 
was present in most cases. This was true also for 
both patients with hypersensitivity pneumonitis, 
thus the positive NTM isolates were regarded as 
colonisation in the course of previously diagnosed 
lung disease and not the allergy to NTM antigens.
The data concerning the risk of NTM infec-
tion in ILD are scarce. Axson et al. [34] found 
ILD in 6% of patients with positive NTM culture 
in UK primary care centres. Ito et al. [35] docu-
mented ILD in 6.6% of subjects with pulmona-
ry MAC-related disease. Park et al. [36] found 
NTMLD in 2% of patients with idiopathic pul-
monary fibrosis, majority of them have not been 
treated with immunosuppressive drugs. 
In our material, the percentage of individuals 
receiving oral corticosteroids due to ILD or CTD 
was larger in NTMLD comparing to the observation 
group (28% and 19%, respectively), nevertheless, 
the difference was not significant. The influence 
of immunosuppressive therapy on NTMLD deve-
lopment was difficult to assess, as in most patients 
it was combined with corticosteroids. 
Brode et al. [37] noted an increased risk of 
NTM-related disease in the patients with rheuma-
toid arthritis receiving anti-TNF therapy, but also 
in those treated with corticosteroids in the dose 
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exceeding 20 mg/day or hydroxychloroquine. 
Our patients who developed NTMLD received 
prednisone in the median dose of 10 mg per day. 
 NTMLD, in our study, was significantly 
more probable in patients with previous history 
of tuberculosis or mycobacteriosis than in the 
remaining ones. This is an important observation, 
as substantial proportion of NTMLD in Poland, 
as well as in Serbia, develop in the individuals 
with past tuberculosis [6, 21, 38]. It is not known, 
whether those patients represent the genetic 
predisposition to mycobacterial lung diseases or 
whether post-tuberculous parenchymal abnor-
malities predispose to colonisation by NTM and 
further NTMLD. 
Our group of patients with positive NTM re-
spiratory specimens also included 4 individuals 
with cystic fibrosis (CF). In 3 of them NTMLD 
developed, in 1 — colonisation was recognised. 
Growing evidence exists in the literature that 
CF is a risk factor for NTMLD [39–41]. The study 
concerning 16 153 CF patients above 12 years of 
age, conducted by Adjemian et al. [40] revealed at 
least one NTM isolation in between 2010 and 2014 
in 20% of them. The growing prevalence of NTM 
isolates was noted: from 11% in 2010 to 13.4% 
in 2014 [40]. Another study concerning 5333 CF 
children and young adults below 16 years of age, 
indicated the increasing prevalence of positive 
cultures for NTM from 1.3% in 2010 to 3.8% 
in 2015 [41]. The types of NTM predominating 
both in children and in adults diagnosed with CF, 
were M. avium/M. intracellulare and M. abscessus 
[40, 41]. In our group of CF patients, the NTM 
identification revealed: M. abscessus — in 1, M. 
intracellulare — in 2, and M.avium — in 1 person. 
In conclusion, the presented analysis of 
patients with positive NTM respiratory isola-
tes showed that factors significantly increasing 
probability of NTMLD recognition were the fol-
lowing: female gender, M. kansasii respiratory 
isolate, or past tuberculosis or mycobacteriosis. 
M. gordonae isolate, as well as higher age and BMI 
were combined with a significantly lower risk of 
NTMLD development.
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